Анестезия и педиатрия - Джордж А.Г.
ISBN 5-225-03821-2
Скачать (прямая ссылка):
683. Parker Rl: Etiology and treatment of acquired coagulopathies in the critically ill edult and child. Crit Can Clin 13:591, 1997
684. Nacht A: The use of blood products in shock. Crit Cere Clin 8:255, 1992
685. Aster RH: NIH consensus conference: platelet transfusion therapy. JAMA 257:1777, 1987
686. Webb IJ, Anderson КС: Risks, costs, and alternatives to platelet transfusions [rcview|. Leu к Lymphoma 34:71,
1999
687. Cehill M R, Ulleyman JS: The rational use of platelet transfusions in children (review). Semin Thromb Hemost 24:567. 1998
688. Novotny VM: Prevention and management of platelet transfusion refractoriness (review). Vox Sang 76:1, 1999
689. Morfini M, Manucci PM, Longo G, et al: Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates. Thromb Res 61:285, 1991
Интенсивная терапия в педиатрии 1143
690. Schwartz RS, Abildgaard CF, Aledort L, et al: Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VHI Stndy Group. N Engl J Med 323.1800,
1990
691. Lusher J M, Salzman PM: Viral safety and inhibitor development associated with factor VI11C ultra-purified from plasma in hemophiliacs previously unexposed to factor VI-11C concentrates. The Monoclate Study Group. Samin Hematol 27, suppl 2:1, 1990
692. Aygoren-Pursun E, Scharrer I: A multicenter pharmaco-surveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb Haemost 78:1352, 1997
693. Kelly KM, Butler RB, Faiace L, et al: Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A. J Pediatr 130:537, 1997
694. Aledort LM: Treatment of von Willebraed’s disease. Mayo Clin Ptoc 66:841, 1991
695. Smith MP, Rice KM, В ro midge ES, et al: Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease. Rood Coagul Fibrinolysis 8:6, 1997
696. Mannucci PM: Treatment of von Willebrand disease (review). Haemophilia 4:661, 1998
697. Manucci PM: Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 8:19, 1986
698. Rose EH, Aledort LM: Nasal spray desmopressin (DDAVP) for mild hemophilia and von Willebrand disease. Ann Intern Med 114:563, 1991
699. Buchanan GR: The Weeding child, p. 212. In Dickerman JD, Lucey JF (eds): The Critically Ilf Child: Diagnosis and Mndical Management. 3rd Ed. WB Saunders, Philadel-
Shia, 1985
liner ME, Kaufman HH, Grahem SH: Disseminated in-travascular coagulation fibrinolytic syndrome following head injury in ohildren: frequency and prognostic implications. J Pediatr 100:687, 1982
701. Kevy S, Fosburg M, Wayne, A et al: Intensive plasma exchange (1PE) and manual whole blood exchaage (WBE) support for patients in acnte hepatic failure, distracted. Transfusion 31, suppl:22S, 1991
702. Cohen JR, Lackner R, Kellar A, Douglas B: The surgical implications of purpura fUlminans. Ann Vase Satg 4:276,
703. Madden RM, Gill JC, Mariar RA: Protein С and protein S levels in two patients with acquired purpura fUlminans. Br J Haematol 75:112, 1990
704. Mariar RA, Montgomery RR, Broekmans AW: Diagnosis and treatment of homozygous protein С deficiency. Report of the Working Party on Homozygous Protein С Deficiency of the Subcommittee on Protein С and Protein
S, International Committee on Thrombosis and Haemostasis. J Pediatr 114:528, 1989
705. Mariar RA, Mastovtch S: Hereditary protein С deficiency: a review of the genetics, clinical presentation, diagnose and treatment. Blood Coagul Fibrinolysis 1:319, 1990
706. Darmstadt GL: Acute infectious purpura fUlminans: pathogenesis and medical management (review). Pediatr Dermatol 15:169, 1998
707. Irazuzta J, McManus ML: Use of topically applied nitroglycerin in the treatment of purpura fUlminans. J Pediatr 117:993, 1990
708. Meyer MT, Irazuzta JE, Tozibikian H: Topical nitroglycerin and pain in purpura fUlminans. J Pedletr 134:639,
1999
709. Irazuzta J, Jarrell J, Portillo A, et al: Compared control -atend application of topical nitroglycerin on purpura fUlminans. W V Med J 94:29, 1998
710. Nowak-Gotti U, Groll A, Kreuz WD, et al: Treatment of dlateminatnd intravascular coagulation with antithrombin
1164 Анестезия в педиатрии
111 concentrate in children with verified infection. Klin Padiatr 204:134, 1992
711. Geison WT, Dickerman JD, Bovill EG, Golden E: Severe acquired protein С deficiency in purpura fulmtnans associated with disseminated intravascular coagulation: treatment with protein С concentrate. Pediatrics 91:418, 1993
712. Rintala E, Seppala OP, Kotilaineri P, et al: Protein С in the treatment of coagulopathy in meningococcal disease. Crit Care Med 26:965, 1998
713. Smith OP, White B, Vaughan D, et al: Use of protein-C concentrate, heparin, and haemodiafiltration in meningo-cocc us-induced purpura fiilminans. Lancet 350:1590, 1997
